BriaCell Therapeutics is a clinical-stage biotech company developing immunotherapies for cancer, with a primary focus on metastatic breast cancer (MBC). BriaCell has no approved products and generates no revenue. The lead candidate, Bria-IMT, is a whole-cell immunotherapy — a genetically engineered human breast cancer cell line designed to activate the immune system to identify and destroy breast cancer tumors. Bria-IMT is being evaluated in a pivotal Phase 3 trial in combination with Incyte's checkpoint inhibitor retifanlimab, targeting advanced MBC patients who have failed prior lines of therapy. The FDA has granted Bria-IMT Fast Track Designation. BriaCell's next-generation candidate, Bria-OTS, is a personalized off-the-shelf immunotherapy in Phase 1/2 development, engineered across multiple cell lines to provide an HLA-matched treatment to over 99% of patients. BriaCell also has preclinical variants targeting prostate, lung, and melanoma cancers, and a majority-owned subsidiary, BriaPro Therapeutics, developing antibody-based therapies. BriaCell funds operations entirely through equity raises and relies on contract manufacturers for clinical production. The company has disclosed substantial doubt about its ability to continue as a going concern.